T. Rowe Price Associates
CARM

T. Rowe Price Associates’s Carisma Therapeutics CARM Stock Holding History

T. Rowe Price Associates’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,725
Closed -$129K – 2966
2022
Q1 		$129K Sell
10,725
-2,720
-20% -$38K ﹤0.01% 2803
2021
Q4 		$219K Buy
13,445
+10,647
+381% +$214K ﹤0.01% 2723
2021
Q3 		$44K Hold
2,798
– – ﹤0.01% 2907
2021
Q2 		$259K Sell
2,798
-3,457
-55% -$220K ﹤0.01% 2634
2021
Q1 		$325K Buy
+6,255
New +$295K ﹤0.01% 2537
2017
Q4 		– Sell
-2,635
Closed -$83K – 2571
2017
Q3 		$83K Hold
2,635
– – ﹤0.01% 2515
2017
Q2 		$83K Buy
2,635
+1,225
+87% +$40.9K ﹤0.01% 2500
2017
Q1 		$62K Hold
1,410
– – ﹤0.01% 2527
2016
Q4 		$54K Hold
1,410
– – ﹤0.01% 2518
2016
Q3 		$79K Buy
+1,410
New +$105K ﹤0.01% 2469

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

T. Rowe Price Associates's CARM Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Carisma Therapeutics (CARM) in Q2 2022, closing a stake of 10,725 shares — an estimated $129K sold.

T. Rowe Price Associates first reported a position in CARM in Q3 2016 and held it in 10 quarters. The position peaked at $325K in Q1 2021. 73 funds tracked by Wall St. Rank hold CARM as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Carisma Therapeutics position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 10,725 Carisma Therapeutics shares in Q2 2022, an estimated $129K.
  • T. Rowe Price Associates first reported a position in Carisma Therapeutics in Q3 2016 and held it in 10 quarters.
  • T. Rowe Price Associates's Carisma Therapeutics position peaked at $325K in Q1 2021.
  • 73 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.